TriSalus Life Sciences

Name

TriSalus Life Sciences

Legal name

TriSalus Life Sciences, Inc.

Website

https://trisaluslifesci.com

Company type

Public

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Interventional Oncology Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Infusion Sets, Catheters & Pump Consumables (HLAHAIAH)

akta.pro secondary industry

Infusion Pumps (Ambulatory/Stationary) (HLAHAIAF)

Keywords

• Interventional oncology devices
• Drug delivery systems
• Immuno-oncology therapeutics
• Medical device manufacturing
• Pressure-enabled infusion

Headquarters

HQ city

Westminster

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Marketing or Sales, Personnel

Revenue model

1. TriNav Infusion System and PEDD Device Sales: Sale of FDA-cleared medical devices including the TriNav Infusion System with SmartValve technology, the PRVI System for pancreatic delivery, and supporting catheters. Revenue is derived from product sales to hospitals and interventional radiology departments.
2. Clinical Trial and Pharmaceutical Development: Revenue potential from the investigational immunotherapy nelitolimod (SD-101), currently in Phase 1 clinical trials for liver and pancreatic tumors, to be delivered via the PEDD platform. The company expects to seek a pharmaceutical partner for further clinical development.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

TriSalus Life Sciences develops and commercializes FDA-cleared infusion catheter systems that use its proprietary Pressure-Enabled Drug Delivery (PEDD) platform with SmartValve technology to deliver therapeutics to solid tumors in the liver and pancreas. The company sells the TriNav Infusion System for liver tumors, the PRVI (Pancreatic Retrograde Venous Infusion) System for pancreatic tumors, and supporting devices such as the TriNav LV Infusion System and TriGuide Guiding Catheters, alongside the investigational TLR9 agonist nelitolimod (SD-101).

Product overview

TriSalus Life Sciences offers an integrated oncology platform combining two FDA-cleared devices—the TriNav® Infusion System and PRVI™ System—utilizing the proprietary Pressure-Enabled Drug Delivery™ (PEDD™) method, with an investigational immunotherapeutic candidate nelitolimod (SD-101). The TriNav product suite (including TriNav LV and TriGuide catheters) enables targeted drug delivery to liver tumors, while PRVI enables retrograde venous delivery to pancreatic tumors. The investigational nelitolimod is a TLR9 agonist being developed to overcome immunosuppression in liver and pancreatic tumors, potentially enabling improved responses to checkpoint inhibitors and other immunotherapies.

Differentiator

Problem solved

Functional benefit

Products and services

• TriNav Infusion System FDA-cleared infusion system with SmartValve technology that enables delivery of therapeutic agents to selected sites in the peripheral vascular system, including tumors in the liver and the entire organ in the presence of micro-metastases. Sold to interventional radiology departments, hospitals, and cancer centers.
• PRVI (Pancreatic Retrograde Venous Infusion) System FDA-cleared device with SmartValve technology for retrograde venous delivery of therapeutics to the peripheral vasculature, specifically designed for targeted delivery to pancreatic tumors via the venous system draining the pancreas. Sold to interventional radiology departments and cancer centers.
• TriNav LV Infusion System Left ventricular infusion system within the TriNav product suite that expands the PEDD device portfolio for improved tumor treatment outcomes. Sold to interventional radiology departments and hospitals.
• TriGuide Guiding Catheters Supporting guiding catheters within the expanded PEDD portfolio designed to provide navigational support during tumor treatment procedures. Sold to interventional radiologists and cancer centers.
• Nelitolimod (SD-101) Investigational toll-like receptor 9 (TLR9) agonist designed to reactivate the immune system within liver and pancreatic tumors by reprogramming immunosuppressive myeloid-derived suppressor cells (MDSCs), potentially enabling deeper responses to checkpoint inhibitors. Administered via the PEDD platform. Currently in Phase 1 clinical trials (PERIO-01, PERIO-03) and intended for partnering with a pharmaceutical company for further development.

Quantifiable outcome

• 48% improvement in drug delivery to target tumors
• +7 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• The University of Texas MD Anderson Cancer CentercoreStrategic or Co-development Partner · 4 May 2026TriSalus initiated the PREDICTT clinical trial at MD Anderson Cancer Center, a prospective study evaluating PEDD technology with the TriNav Infusion System in patients with liver tumors undergoing Y90 radioembolization therapy. This expands an existing collaboration between TriSalus and MD Anderson aimed at generating clinical evidence to optimize locoregional therapies.
• Tulane UniversityminorStrategic or Co-development Partner · 9 April 2026Academic collaboration for clinical and preclinical research on PEDD technology applications in liver-directed therapies and embolization techniques, including presentations at the Society of Interventional Radiology 2026 Annual Scientific Meeting.
• Rutgers Robert Wood Johnson Medical SchoolminorStrategic or Co-development Partner · 9 April 2026Academic collaboration contributing preclinical and clinical research on PEDD technology applications in liver-directed therapies and uterine artery embolization, with findings presented at SIR 2026.
• Geo-MedcoreChannel Partner/ Reseller/ Distributor · 11 December 2024Partnership with Geo-Med to expand availability of the TriNav Infusion System to Veterans Health Administration (VA) medical centers, enabling broader access to TriSalus's drug delivery technology within the VA healthcare system.
• UC San Diego Moores Cancer CenterminorStrategic or Co-development PartnerPreclinical research collaboration demonstrating benefits of PEDD delivery of investigational TLR9 agonist in combination with checkpoint inhibitor therapy for pancreatic tumors in murine models, presented at ASCO GI 2023.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Boston Scientific: Acquired BTG including TheraSphere Y-90 radioembolization and interventional oncology franchises. Directly competes with TriSalus in liver-directed therapies for HCC and liver metastases, with substantially larger commercial scale and broader device portfolio.
• Cook Medical: Long-established manufacturer of embolization coils, microcatheters, and IR accessories. Competes with TriSalus in the supply of consumables and devices used by interventional radiologists treating liver and pancreatic tumors.
• Varian (Siemens Healthineers): Provides interventional oncology and radiotherapy solutions including embolization planning software and radioembolization programs. TriSalus's PEDD approach is positioned alongside Varian's broader interventional oncology portfolio in HCC.
• Penumbra: Develops embolization, thrombectomy, and interventional oncology products including the LANTERN microcatheter. Competes with TriSalus in IR catheter-based drug delivery and embolization procedures for liver cancer.
• Merit Medical Systems: Manufactures microcatheters, embolization devices, and oncology delivery systems used in interventional radiology procedures. Competes with TriSalus in catheter-based delivery for TACE and other embolization procedures in liver tumors.

Emerging players

• IceCure Medical: Developer of cryoablation systems for tumor destruction, including liver and breast cancer. Competes with TriSalus for interventional oncology procedure volumes and physician mindshare in tumor-directed therapies.
• HistoSonics: Developer of histotripsy platforms for non-invasive destruction of liver tumors. Represents an emerging non-drug delivery approach to HCC and liver metastases that competes for the same interventional oncology patient pool.
• Replimune: Clinical-stage biotech developing oncolytic immunotherapy for solid tumors. TriSalus's nelitolimod/TLR9 program pursues a related immunotherapy angle for liver and pancreatic tumors, making Replimune a relevant emerging comparator in regional immuno-oncology.

Direct peers

• Guerbet: Provides Lipiodol and other contrast/drug delivery agents used in TACE procedures for HCC. TriSalus's PEDD platform competes with conventional Lipiodol-based chemoembolization in hepatocellular carcinoma treatment.
• Sirtex Medical: Developer of SIR-Spheres Y-90 radioembolization microspheres for liver cancer. Competes head-to-head with TriSalus's TriNav/PEDD platform in HCC and colorectal liver metastases, addressing similar delivery challenges in liver-directed oncology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/SurefireMedical
• LinkedInlinkedin.com/company/surefire-medical-inc-
• Facebookfacebook.com/surefiremedical

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds8 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TriSalus Life Sciences